Clinical Trials
6 trialsNCT02959463 2026-05-27
Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02399371 2026-05-08
Pembrolizumab in Treating Patients With Malignant Mesothelioma
University of Chicago
Phase 2 Completed
NCT03126630 2026-04-01
Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT04914897 2025-10-02
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)
Sanofi
Phase 2 Terminated
NCT03233724 2023-05-31
Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT03175172 2019-04-04
Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM)
Aduro Biotech, Inc.
Phase 2 Terminated